These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29297701)

  • 1. Antirheumatic biologics in pregnant patients: a call for studies to address the knowledge gap.
    Østensen M
    Expert Rev Clin Immunol; 2018 Feb; 14(2):95-97. PubMed ID: 29297701
    [No Abstract]   [Full Text] [Related]  

  • 2. Characteristics and outcomes of rheumatoid arthritis patients who started biosimilar infliximab.
    Sung YK; Cho SK; Kim D; Won S; Choi CB; Bang SY; Hong SJ; Kim HA; Koh EM; Lee HS; Suh CH; Yoo DH; Bae SC
    Rheumatol Int; 2017 Jun; 37(6):1007-1014. PubMed ID: 28214924
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biosimilars and drug development in allergic and immunologic diseases.
    Bonini S; Bonini M
    J Allergy Clin Immunol; 2017 May; 139(5):1461-1464. PubMed ID: 28359671
    [No Abstract]   [Full Text] [Related]  

  • 4. Use of Biologics and Biosimilars in Rheumatology.
    Sharma SK
    J Assoc Physicians India; 2017 May; 65(5 Suppl):9-14. PubMed ID: 28836745
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-tumor necrosis factor patent expiration and the risks of biocopies in clinical practice.
    Scheinberg M; Castañeda-Hernández G
    Arthritis Res Ther; 2014 Dec; 16(6):501. PubMed ID: 25677586
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of a biosimilar rituximab in biologic naïve patients with active rheumatoid arthritis.
    Roshique KK; Ravindran V
    Clin Rheumatol; 2015 Jul; 34(7):1289-92. PubMed ID: 26032432
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psoriasis in pregnancy: a review (II).
    Ruiz V; Manubens E; Puig L
    Actas Dermosifiliogr; 2014 Nov; 105(9):813-21. PubMed ID: 24314892
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety of biologic agents for the management of rheumatic diseases during pregnancy.
    D'Gama JD; Bermas BL
    Curr Opin Rheumatol; 2024 May; 36(3):184-190. PubMed ID: 38456470
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unanswered questions in the management of axial spondyloarthritis: an opinion piece.
    Baraliakos X; Deodhar A
    Clin Rheumatol; 2014; 33(10):1359-65. PubMed ID: 24941929
    [No Abstract]   [Full Text] [Related]  

  • 10. Efficacy and Safety Outcomes for Originator TNF Inhibitors and Biosimilars in Rheumatoid Arthritis and Psoriasis Trials: A Systematic Literature Review.
    Moots RJ; Curiale C; Petersel D; Rolland C; Jones H; Mysler E
    BioDrugs; 2018 Jun; 32(3):193-199. PubMed ID: 29790131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching from Other Biologics to ZRC3197 (Adalimumab Biosimilar) in Patients with Spondyloarthropathy: A Prospective Evaluation from Real-Life Clinical Practice.
    Kapoor S
    J Assoc Physicians India; 2017 May; 65(5 Suppl):26-29. PubMed ID: 28836748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis.
    Nam JL; Takase-Minegishi K; Ramiro S; Chatzidionysiou K; Smolen JS; van der Heijde D; Bijlsma JW; Burmester GR; Dougados M; Scholte-Voshaar M; van Vollenhoven R; Landewé R
    Ann Rheum Dis; 2017 Jun; 76(6):1113-1136. PubMed ID: 28283512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Comparison of Treatment Guidelines for Ulcerative Colitis: Role of Biologics].
    Bae JH; Yang DH
    Korean J Gastroenterol; 2018 Apr; 71(4):192-195. PubMed ID: 29684967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rheumatoid arthritis and pregnancy: impediments to optimal management of both biologic use before, during and after pregnancy.
    Williams M; Chakravarty EF
    Curr Opin Rheumatol; 2014 May; 26(3):341-6. PubMed ID: 24663107
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A scientific update on biosimilar infliximab (CT-P13) in rheumatic diseases.
    Taylor P
    Expert Rev Clin Immunol; 2015; 11 Suppl 1():S1-4. PubMed ID: 26395831
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An FDA perspective on the assessment of proposed biosimilar therapeutic proteins in rheumatology.
    Nikolov NP; Shapiro MA
    Nat Rev Rheumatol; 2017 Feb; 13(2):123-128. PubMed ID: 28053335
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Focusing on the use of biologics in rheumatoid arthritis].
    Devauchelle-Pensec V; Guellec D
    Rev Prat; 2015 May; 65(5):687-8. PubMed ID: 26165113
    [No Abstract]   [Full Text] [Related]  

  • 18. The biologics of ulcerative colitis.
    Macaluso FS; Renna S; Orlando A; Cottone M
    Expert Opin Biol Ther; 2017 Feb; 17(2):175-184. PubMed ID: 27960557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estimation of cost savings between 2011 and 2014 attributed to infliximab biosimilar in the South Korean healthcare market: real-world evidence using a nationwide database.
    Kim J; Ha D; Song I; Park H; Lee SW; Lee EK; Shin JY
    Int J Rheum Dis; 2018 Jun; 21(6):1227-1236. PubMed ID: 29667324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is it time for biosimilars in autoimmune diseases?
    Cuadrado MJ; Sciascia S; Bosch X; Khamashta MA; Ramos-Casals M
    Autoimmun Rev; 2013 Aug; 12(10):954-7. PubMed ID: 23542505
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.